- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Chu on the Importance of Identifying MSI Status in mCRC
Edward Chu, MD, MMS, discusses the importance of identifying patients with microsatellite instability–high metastatic colorectal cancer.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Edward Chu, MD, MMS, director and professor of medicine and molecular pharmacology at Albert Einstein Cancer Center, and vice president for cancer medicine at Montefiore Medicine, discusses the importance of identifying patients with microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC).
Approximately 5% of patients with mCRC will express an MSI-H phenotype, says Chu. Despite its rarity, MSI-H is an important characteristic of a patient’s disease, says Chu.
Similar to HER2, RAS, and NTRK aberrations, MSI-H can help inform critical treatment decisions, Chu adds. When molecular* abnormalities are identified, patients can be treated appropriately with personalized therapy, Chu adds.
Notably, during the 2020 ASCO Virtual Scientific Program, the concept of precision medicine in mCRC was a major theme, concludes Chu.
Related Content:
